Together, these findings demonstrate that leukocytespecific ADAM17 deletion leads to reduced tumor onset that correlates with decreased proliferation and reduced numbers of K14-positive cells within the tumors, suggesting that loss of ADAM17 in leukocytes may affect expansion of the basal cell population. This evidence concerns the gene ADAM17 and neoplasm.